Lineage Cell Therapeutics (LCTX) Net Margin (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Net Margin came in at 278.96% in Q1 2026, up 17444.0% year-on-year from N/an in Q1 2025, and down 216.67% quarter-over-quarter from 88.09% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Net Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 278.96% for Q1 2026.
- On a quarterly basis, Net Margin rose 17444.0% year-over-year to 278.96% in Q1 2026; TTM through Mar 2026 was 351.95%, a 15488.0% decrease from a year earlier, with the FY2025 full-year figure at 435.33%, down 23971.0% from the prior year.
- Net Margin eased to 278.96% in Q1 2026 per LCTX's latest filing, from 88.09% in the prior quarter.
- Across five years, Net Margin topped out at 79.41% in Q3 2024 and bottomed at 815.01% in Q2 2025.
- The 5-year median for Net Margin is 225.77% (2023), against an average of 303.98%.
- Across the five-year window, Net Margin surged 82077 bps in 2022 and plunged 43260 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 330.08% in 2022, then surged by 32 bps to 225.77% in 2023, then soared by 50 bps to 113.32% in 2024, then gained by 22 bps to 88.09% in 2025, then sank by 217 bps to 278.96% in 2026.
- Per Business Quant, the three latest LCTX Net Margin figures stand at 278.96% (Q1 2026), 88.09% (Q4 2025), and 512.01% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | -278.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -278.96% |
| Dec 31, 2025 | -88.09% |
| Sep 30, 2025 | -512.01% |
| Jun 30, 2025 | -815.01% |
| Mar 31, 2025 | -453.40% |
| Dec 31, 2024 | -113.32% |
| Sep 30, 2024 | -79.41% |
| Jun 30, 2024 | -410.01% |
| Mar 31, 2024 | -454.16% |
| Dec 31, 2023 | -225.77% |
| Sep 30, 2023 | -574.48% |
| Jun 30, 2023 | -161.33% |
| Mar 31, 2023 | -184.58% |
| Dec 31, 2022 | -330.08% |
| Sep 30, 2022 | -202.64% |
| Jun 30, 2022 | -148.96% |
| Mar 31, 2022 | -135.44% |
| Dec 31, 2021 | -56.02% |
| Sep 30, 2021 | -345.11% |
| Jun 30, 2021 | -969.73% |